{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T13:35:23Z","timestamp":1786628123002,"version":"build-2736575974"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Androgen Deprivation Therapy (ADT) in prostate cancer (PCa) is associated with bone loss and increased fracture risk. Previous studies on the effects of ADT on bone have focused on areal bone mineral density (aBMD) from dual-energy X-ray absorptiometry (DXA) at the central skeleton, while the effects on peripheral aBMD, bone microarchitecture, and bone strength are less well studied.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this two-year observational study, we examined the changes in aBMD and volumetric BMD, bone area, microarchitecture, and strength from high-resolution peripheral quantitative CT (HR-pQCT) after ADT initiation in men with PCa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 115 men were included, of whom 43 were treated with zoledronic acid (ZOL+) from ADT initiation and the other 72 were not (ZOL \u2212), according to national guidelines. DXA (lumbar spine, total hip, femoral neck, total body, left and right arm, left and right leg) and HR-pQCT (distal radius, distal tibia) measurements were performed at ADT initiation (T0) and after 24 months (T2). aBMD in the ZOL\u2212 group significantly decreased between T0 and T2 at all measurement locations (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0&amp;lt;\u00a00.05), with a mean decrease ranging between -3.0\u00a0\u00b1\u00a07.4% (left leg) and -5.0\u00a0\u00b1\u00a05.1% (femoral neck). In the ZOL+ group, only lumbar spine and right leg aBMD significantly changed (+3.6\u00a0\u00b1\u00a04.3% and -2.3\u00a0\u00b1\u00a03.2%, respectively). Using HR-pQCT, it was found that bone area, volumetric BMD, microarchitecture, and strength significantly declined at the distal radius and tibia in both the ZOL \u2013 and ZOL+ group. The most significant changes were noted at the distal radius in cortical area (ZOL-: -10.1\u00a0\u00b1\u00a05.9%; ZOL+: -6.5\u00a0\u00b1\u00a05.1%), total BMD (ZOL-: -8.8\u00a0\u00b1\u00a04.2%; ZOL+: -5.5\u00a0\u00b1\u00a03.7%), and failure load (ZOL-: -11.6\u00a0\u00b1\u00a08.0%; ZOL+: -10.2\u00a0\u00b1\u00a08.2%).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Two-year ADT in men with PCa led to a significant decrease of central and peripheral aBMD and of HR-pQCT derived bone microstructure and strength at the distal radius and tibia. Although ZOL prevented loss of aBMD in central and peripheral bone, bone area, volumetric BMD, microarchitecture, and strength significantly declined at the distal radius and tibia. These findings emphasize the importance of early risk assessment and guideline-based intervention and highlight the need for continued improvement of bone health strategies in men with prostate cancer undergoing ADT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1862001","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:55:11Z","timestamp":1786625711000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Central and peripheral areal BMD, bone microarchitecture, and strength after initiation of androgen deprivation therapy in men with prostate cancer: a two-year follow-up study"],"prefix":"10.3389","volume":"17","author":[{"given":"Marsha M.","family":"van Oostwaard","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, VieCuri Medical Center","place":["Venlo, Netherlands"]},{"name":"Department of Rheumatology, Institute of Nutrition and Translational Research In Metabolism (NUTRIM), Maastricht University Medical Center","place":["Maastricht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa S.A.M.","family":"Bevers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, VieCuri Medical Center","place":["Venlo, Netherlands"]},{"name":"Department of Rheumatology, Institute of Nutrition and Translational Research In Metabolism (NUTRIM), Maastricht University Medical Center","place":["Maastricht, Netherlands"]},{"name":"Department of Biomedical Engineering, Eindhoven University of Technology","place":["Eindhoven, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna H.M.","family":"Driessen","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Toxicology, Maastricht University Medical Center+","place":["Maastricht, Netherlands"]},{"name":"Department of Clinical Pharmacy, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University","place":["Maastricht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline E.","family":"Wyers","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, VieCuri Medical Center","place":["Venlo, Netherlands"]},{"name":"Department of Rheumatology, Institute of Nutrition and Translational Research In Metabolism (NUTRIM), Maastricht University Medical Center","place":["Maastricht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop P.","family":"van den Bergh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, VieCuri Medical Center","place":["Venlo, Netherlands"]},{"name":"Department of Rheumatology, Institute of Nutrition and Translational Research In Metabolism (NUTRIM), Maastricht University Medical Center","place":["Maastricht, Netherlands"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.48252","article-title":"An in-depth look into the epidemiological and etiological aspects of prostate cancer: a literature review","volume":"15","author":"Al-Ghazawi","year":"2023","journal-title":"Cureus"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s44197-023-00103-6","article-title":"Global burden of prostate cancer and association with socioeconomic status, 1990-2019: a systematic analysis from the Global Burden of Disease Study","volume":"13","author":"Zhang","year":"2023","journal-title":"J Epidemiol Glob Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2013.05.001","article-title":"Androgens and prostate cancer: pathogenesis and deprivation therapy","volume":"27","author":"Grossmann","year":"2013","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21799","article-title":"Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE)","volume":"106","author":"Kawakami","year":"2006","journal-title":"Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2018-0619","article-title":"Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis","volume":"15","author":"Sun","year":"2019","journal-title":"Future Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041943","article-title":"Risk of fracture after androgen deprivation for prostate cancer","volume":"352","author":"Shahinian","year":"2005","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-018-4722-3","article-title":"Patients with prostate cancer and androgen deprivation therapy have increased risk of fractures-a study from the fractures and fall injuries in the elderly cohort (FRAILCO)","volume":"30","author":"Wallander","year":"2019","journal-title":"Osteoporos Int"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-024-07180-8","article-title":"The risk of fragility fractures in men with prostate cancer treated with androgen deprivation therapy","volume":"35","author":"van Oostwaard","year":"2024","journal-title":"Osteoporos Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01497-4","article-title":"Androgen deprivation therapy-related fracture risk in prostate cancer: an insurance claims database study in Japan","volume":"42","author":"Matsushima","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2005-0183","article-title":"Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer","volume":"90","author":"Greenspan","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B12","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/ncpuro0995","article-title":"Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know","volume":"5","author":"Higano","year":"2008","journal-title":"Nat Clin Pract Urol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2024.100611","article-title":"The impact of androgen deprivation therapy on bone microarchitecture in men with prostate cancer: A longitudinal observational study (The ANTELOPE Study)","volume":"47","author":"Handforth","year":"2024","journal-title":"J Bone Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019","article-title":"Bone health in cancer: ESMO Clinical Practice Guidelines","volume":"31","author":"Coleman","year":"2020","journal-title":"Ann Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur Urol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2019.06.005","article-title":"Bone mineral density, structure, distribution and strength in men with prostate cancer treated with androgen deprivation therapy","volume":"127","author":"Dalla Via","year":"2019","journal-title":"Bone"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.319","article-title":"Cross-sectional analysis of the association between fragility fractures and bone microarchitecture in older men: the STRAMBO study","volume":"26","author":"Szulc","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4808","article-title":"A Fracture Risk Assessment Tool for High Resolution Peripheral Quantitative Computed Tomography","volume":"38","author":"Whittier","year":"2023","journal-title":"J Bone Miner Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2010-0902","article-title":"Structural decay of bone microarchitecture in men with prostate cancer treated with androgen deprivation therapy","volume":"95","author":"Hamilton","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117465","article-title":"Altered vertebral biomechanical properties in prostate cancer patients following androgen deprivation therapy","volume":"195","author":"Gibson","year":"2025","journal-title":"Bone"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4106","article-title":"Differing Effects of Zoledronic Acid on Bone Microarchitecture and Bone Mineral Density in Men Receiving Androgen Deprivation Therapy: A Randomized Controlled Trial","volume":"35","author":"Cheung","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16152665","article-title":"Development of a Multidisciplinary Care Pathway for Fracture Prevention in Men with Prostate Cancer at Initiation of Androgen Deprivation Therapy","volume":"16","author":"van Oostwaard","year":"2024","journal-title":"Cancers"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2022.100465","article-title":"High prevalence of vertebral fractures at initiation of androgen deprivation therapy for prostate cancer","volume":"38","author":"van Oostwaard","year":"2023","journal-title":"J Bone Oncol"},{"key":"B25","article-title":"CBO Richtlijn Osteoporose en fractuurpreventie, derde herziening","author":"lems","year":"2011"},{"key":"B26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s11657-024-01378-3","article-title":"The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena","volume":"19","author":"van den Bergh","year":"2024","journal-title":"Arch Osteoporos"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2013.08.001","article-title":"2013 International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases","volume":"16","author":"Watts","year":"2013","journal-title":"J Clin Densitom"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-020-05438-5","article-title":"Guidelines for the assessment of bone density and microarchitecture in vivo using high-resolution peripheral quantitative computed tomography","volume":"31","author":"Whittier","year":"2020","journal-title":"Osteoporos Int"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2011.10.003","article-title":"Visual grading of motion induced image degradation in high resolution peripheral computed tomography: impact of image quality on measures of bone density and micro-architecture","volume":"50","author":"Pialat","year":"2012","journal-title":"Bone"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.4114","article-title":"Sex- and Site-Specific Reference Data for Bone Microarchitecture in Adults Measured Using Second-Generation HR-pQCT","volume":"35","author":"Whittier","year":"2020","journal-title":"J Bone Miner Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/s8756-3282(02)00736-6","article-title":"Estimation of distal radius failure load with micro-finite element analysis models based on three-dimensional peripheral quantitative computed tomography images","volume":"30","author":"Pistoia","year":"2002","journal-title":"Bone"},{"key":"B33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s001980050008","article-title":"Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women","volume":"11","author":"Patel","year":"2000","journal-title":"Osteoporos Int"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocd.2019.07.001","article-title":"Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics","volume":"22","author":"Shuhart","year":"2019","journal-title":"J Clin Densitom"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-007-0382-4","article-title":"Precision and accuracy of measuring changes in bone mineral density by dual-energy X-ray absorptiometry","volume":"18","author":"Tothill","year":"2007","journal-title":"Osteoporos Int"},{"key":"B36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.jocd.2017.01.006","article-title":"Precision of Second-Generation High-Resolution Peripheral Quantitative Computed Tomography: Intra- and Intertester Reproducibilities and Factors Involved in the Reproducibility of Cortical Porosity","volume":"21","author":"Chiba","year":"2018","journal-title":"J Clin Densitom"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s00198-020-05449-2","article-title":"Longitudinal bone microarchitectural changes are best detected using image registration","volume":"31","author":"Kemp","year":"2020","journal-title":"Osteoporos Int"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing","volume":"57","author":"Benjamini","year":"2018","journal-title":"J R Stat Soc \u2013 Ser B: Stat Method"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.7326\/M16-2577","article-title":"Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis","volume":"167","author":"Alibhai","year":"2017","journal-title":"Ann Intern Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1007\/s00774-024-01537-z","article-title":"Temporal declines in bone mineral density and trabecular bone score during androgen deprivation therapy","volume":"42","author":"Hara","year":"2024","journal-title":"J Bone Miner Metab"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbo.2025.100713","article-title":"Alteration of bone architecture following androgen deprivation therapy in patients with prostate cancer using 3D-modeling from hip DXA","volume":"55","author":"Park","year":"2025","journal-title":"J Bone Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8010113","article-title":"Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis","volume":"8","author":"Kim","year":"2019","journal-title":"J Clin Med"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/s0022-5347(05)00999-7","article-title":"Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression","volume":"175","author":"Morote","year":"2006","journal-title":"J Urol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-013-2477-2","article-title":"Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer","volume":"28","author":"Shahinian","year":"2013","journal-title":"J Gen Intern Med"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1007\/s001980070037","article-title":"Effects of body size and skeletal site on the estimated prevalence of osteoporosis in women and men","volume":"11","author":"Melton","year":"2000","journal-title":"Osteoporos Int"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08483.x","article-title":"Long-term changes in bone mineral density and predicted fracture risk in patients receiving androgen-deprivation therapy for prostate cancer, with stratification of treatment based on presenting values","volume":"104","author":"Wadhwa","year":"2009","journal-title":"BJU Int"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2013.04.029","article-title":"A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy","volume":"11","author":"Lang","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-019-04935-6","article-title":"Validation of distal radius failure load predictions by homogenized- and micro-finite element analyses based on second-generation high-resolution peripheral quantitative CT images","volume":"30","author":"Arias-Moreno","year":"2019","journal-title":"Osteoporos Int"},{"key":"B49","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.jbiomech.2018.08.030","article-title":"Harmonizing finite element modelling for non-invasive strength estimation by high-resolution peripheral quantitative computed tomography","volume":"80","author":"Whittier","year":"2018","journal-title":"J Biomech"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1862001\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T12:55:13Z","timestamp":1786625713000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1862001\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":49,"alternative-id":["10.3389\/fendo.2026.1862001"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1862001","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"article-number":"1862001"}}